Simon P. Heaton

2.0k citations

17 papers · 1.1k indexed · h-index 11

Co-authors: Robert W. Wilkinson Michelle D. Garrett Rajesh Odedra Timothy A. Yap Kyriakos P. Papadopoulos Ivy Fearen Len Tiu Wright Johann S. de Bono
Topics: PI3K/AKT/mTOR signaling in cancer (7 papers)Microtubule and mitosis dynamics (5 papers)Cancer-related Molecular Pathways (4 papers)
Cited by: Cell Biology Oncology Molecular Biology
Journals: Journal of Clinical Oncology Cancer Research Clinical Cancer Research
Partner nations: United Kingdom United States France

In The Last Decade

Simon P. Heaton

17 papers receiving 1.1k citations

Peers

Countries citing papers authored by Simon P. Heaton

Since Specialization

Citations

This map shows the geographic impact of Simon P. Heaton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon P. Heaton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon P. Heaton more than expected).

Fields of papers citing papers by Simon P. Heaton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon P. Heaton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon P. Heaton. The network helps show where Simon P. Heaton may publish in the future.

Co-authorship network of co-authors of Simon P. Heaton

This figure shows the co-authorship network connecting the top 25 collaborators of Simon P. Heaton. A scholar is included among the top collaborators of Simon P. Heaton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon P. Heaton. Simon P. Heaton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma 2015 ·Molecular Oncology ·Jennifer R. Smith,Lucas Moreno,Simon P. Heaton,Louis Chesler,Andrew D.J. Pearson,Michelle D. Garrett	16
2	The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models 2012 ·British Journal of Cancer ·Sarah V. Holt,Armelle Logié,Rajesh Odedra,Annabelle Heier,Simon P. Heaton,Denis Alférez,Barry R. Davies,Robert W. Wilkinson,Paul D. Smith	92
3	Intratracheal and oral administration of SM‐276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer 2012 ·International Journal of Cancer ·(unknown),Simon J. Dovedi,Masashi Murata,Hiroyuki Matsui,Andrew J. Leishman,John Bell,Douglas Ferguson,Simon P. Heaton,(unknown),Hideyuki Tomizawa,(unknown),Haruo Takaku,Robert W. Wilkinson,Hideyuki Harada	23
4	A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors. 2012 ·Journal of Clinical Oncology ·Aurelius Omlin,James Spicer,Debashis Sarker,David J. Pinato,Roshan Agarwal,Philippe A. Cassier,Chara Stavraka,(unknown),Aneta Suder,Suzanne Allan,Simon P. Heaton,Shaun Decordova,Lorna Pope,(unknown),Kohei Noguchi,Keith Jones,(unknown),(unknown),Udai Banerji,Sarah P. Blagden	4
5	Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers. 2011 ·Journal of Clinical Oncology ·Tami Yap,Libo Yan,(unknown),David Olmos,Ivy Fearen,Richard D. Baird,Kyriakos P. Papadopoulos,Nina Tunariu,Andrea Biondo,Heike Keilhack,(unknown),(unknown),(unknown),Celia L. Carpenter,Shaun Decordova,Simon P. Heaton,May Garrett,Dan M. Sullivan,Johann S. de Bono,A. W. Tolcher	9
6	First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors 2011 ·Journal of Clinical Oncology ·Timothy A. Yap,Yan Li,Amita Patnaik,Ivy Fearen,David Olmos,Kyriakos P. Papadopoulos,Richard D. Baird,Liliana Delgado,Adekemi Taylor,Lisa Lupinacci,Ruth Riisnaes,Lorna Pope,Simon P. Heaton,George Thomas,Michelle D. Garrett,Daniel M. Sullivan,Johann S. de Bono,Anthony W. Tolcher	433
7	Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors. 2011 ·Journal of Clinical Oncology ·Andrea Biondo,Tami Yap,Long Yan,Amita Patnaik,Ivy Fearen,Richard D. Baird,Kyriakos P. Papadopoulos,(unknown),(unknown),Lorena Lupinacci,(unknown),Shaun Decordova,(unknown),Simon P. Heaton,May Garrett,Dan M. Sullivan,Johann S. de Bono,A. W. Tolcher	16
8	Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930 2010 ·Molecular Cancer Therapeutics ·Timothy A. Yap,Mike I. Walton,(unknown),Melanie Valenti,Alexis de Haven Brandon,Paul D. Eve,Ruth Ruddle,Simon P. Heaton,Alan T. Henley,Lisa Pickard,Gowri Vijayaraghavan,John Caldwell,Neil T. Thompson,Wynne Aherne,Florence I. Raynaud,Suzanne A. Eccles,Paul Workman,Ian Collins,Michelle D. Garrett	59
9	AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth 2010 ·Molecular Cancer Therapeutics ·(unknown),(unknown),Timothy A. Yap,Simon P. Heaton,Mike I. Walton,Steven J. Woodhead,Lynsey Fazal,Matthias Reule,Thomas G. Davies,Lisa C. A. Seavers,Victoria Lock,John F. Lyons,Neil T. Thompson,Paul Workman,Michelle D. Garrett	50
10	Abstract 27: First dose-finding study in cancer patients (pts) of a potent, selective, allosteric AKT inhibitor MK2206 (MK), incorporating pharmacodynamic (PD) and predictive biomarkers and showing profound pathway blockade 2010 ·Cancer Research ·Timothy A. Yap,Kyriakos P. Papadopoulos,Ivy Fearen,Christopher L. Carpenter,Liliana Delgado,Adekemi Taylor,David Olmos,(unknown),(unknown),Shaun Decordova,Mike I. Walton,Simon P. Heaton,Michelle D. Garrett,(unknown),Amita Patnaik,Daniel M. Sullivan,(unknown),Johann S. de Bono,Anthony W. Tolcher	3
11	Abstract B135: First-in-man, first-in-class phase I study of two schedules of MK-2206, a novel oral Akt inhibitor, in patients (pts) with advanced solid tumors, including ovarian and castration resistant prostate cancer (CRPC) 2009 ·Molecular Cancer Therapeutics ·Timothy A. Yap,Kyriakos P. Papadopoulos,Ivy Fearen,Christopher Carpenter,Liliana Delgado,Adekemi Taylor,(unknown),David Olmos,André T. Brunetto,Daniel Shao-Weng Tan,Shaun Decordova,Simon P. Heaton,Michelle D. Garrett,Amita Patnaik,Daniel M. Sullivan,Yan Li,Johann S. de Bono,Anthony W. Tolcher	1
12	Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: Selective inhibitors of Aurora B kinase with potent anti-tumor activity 2008 ·Bioorganic & Medicinal Chemistry Letters ·Kevin M. Foote,Andrew Mortlock,Nicola M. Heron,Frédéric Jung,George B. Hill,Georges Pasquet,Madeleine C. Brady,Stephen Green,Simon P. Heaton,(unknown),Nicholas Keen,Rajesh Odedra,Stephen R. Wedge,Robert W. Wilkinson	32
13	Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity 2008 ·Molecular Cancer Therapeutics ·Jeffrey L. Cummings,Cassandra L. Hodgkinson,Rajesh Odedra,Patrizia Sini,Simon P. Heaton,Kirsten Mundt,Tim Ward,Robert W. Wilkinson,Jim Growcott,Andrew Hughes,Caroline Dive	50
14	AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis 2007 ·Clinical Cancer Research ·Robert W. Wilkinson,Rajesh Odedra,Simon P. Heaton,Stephen R. Wedge,Nicholas Keen,Claire Crafter,John R. Foster,Madeleine C. Brady,Alison Bigley,(unknown),Kate F. Byth,Nigel Barrass,Kirsten Mundt,Kevin M. Foote,Nicola M. Heron,Frédéric Jung,Andrew Mortlock,(unknown),Stephen Green	278
15	AZD1152: A highly potent and specific aurora kinase inhibitor. 2006 ·Cancer Research ·Robert W. Wilkinson,Nicholas Keen,Rajesh Odedra,Simon P. Heaton,Stephen R. Wedge,Kevin M. Foote,Andrew Mortlock,Frédéric Jung,Nicola M. Heron,Madeleine C. Brady,Mike Walker,(unknown),Nigel Barrass,J. J. Foster,Stephen Green	6
16	469 POSTER Detection of surrogate markers of apoptosis in the peripheral blood of a preclinical tumour model treated with a selective inhibitor of Aurora B kinase (AZD1152) 2006 ·European Journal of Cancer Supplements ·Robert W. Wilkinson,Rajesh Odedra,Simon P. Heaton,Claire Crafter,J Growcott,Kirsten Mundt,Jeff Cummings,Timothy H. Ward,(unknown),Caroline Dive	1
17	Fair Trade marketing: an exploration through qualitative research 2006 ·Journal of Strategic Marketing ·Len Tiu Wright,Simon P. Heaton	51

About Simon P. Heaton

Simon P. Heaton is a scholar working on Cell Biology, Oncology and Cancer Research, having authored 17 papers that have together received 1.1k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (7 papers), Microtubule and mitosis dynamics (5 papers) and Cancer-related Molecular Pathways (4 papers). The work is most often cited by research in Cell Biology (266 citations), Oncology (409 citations) and Molecular Biology (748 citations). Simon P. Heaton has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Robert W. Wilkinson, Michelle D. Garrett, Rajesh Odedra, Timothy A. Yap, Kyriakos P. Papadopoulos, Ivy Fearen, Len Tiu Wright, Johann S. de Bono, David Olmos and Amita Patnaik. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact